MarketCap
Alnylam Pharmaceuticals ALNY
$ 155.97
-0.34%
Facebook
X
Telegram
Alnylam Pharmaceuticals ROE Ratio | ALNY
Annual ROE Ratio Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.76 | -414.62 | 199.53 | 714.91 | -144.99 | -84.46 | -61.59 | -58.49 | -27.79 | -44.57 | -22.94 | -38.49 | -33.0 | -79.08 | -48.86 | -27.5 | -26.74 | -12.99 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 714.91 | -414.62 | -9.55 |
Quarterly ROE Ratio Alnylam Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 136.86 | 63.72 | 47.29 | -91.7 | -486.99 | 76.69 | 111.04 | 298.38 | 554.14 | 71.11 | 108.19 | 176.85 | 866.07 | 640.85 | 513.79 | 338.71 | -288.49 | -153.12 | -114.84 | -94.86 | -88.65 | -79.24 | -71.12 | -66.35 | -58.48 | -58.16 | -56.42 | -53.47 | -57.08 | -54.68 | -50.97 | -42.78 | -37.8 | -38.25 | -43.12 | -47.34 | -45.98 | -43.64 | -39.39 | -34.29 | -29.85 | -26.74 | -21.47 | -16.58 | -15.64 | -15.22 | -38.1 | -47.79 | -52.9 | -54.12 | -30.73 | -65.15 | -66.19 | -67.17 | -70.04 | -35.77 | -35.11 | -38.36 | -43.78 | -36.04 | -31.69 | -30.4 | -4.38 | -5.99 | -8.84 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 866.07 | -486.99 | 12.59 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Corner Growth Acquisition Corp.
COOL
|
108.33 | - | -0.89 % | $ 114 M |  USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
12.23 | $ 306.2 | 2.41 % | $ 5.92 B | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-61.06 | $ 7.95 | 2.57 % | $ 535 B |  Britain |
 |
Mersana Therapeutics
MRSN
|
727.65 | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
21.38 | $ 53.62 | 1.67 % | $ 3.47 B |  Danmark |
 |
Allakos
ALLK
|
-146.95 | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-370.23 | - | - | $ 717 K | USA |
 |
Ionis Pharmaceuticals
IONS
|
-77.98 | $ 39.67 | 2.24 % | $ 6.35 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
-55.97 | $ 8.1 | 4.59 % | $ 2.89 M | USA |
 |
Immuron Limited
IMRN
|
-64.64 | $ 0.82 | -3.68 % | $ 189 M |  Australia |
 |
G1 Therapeutics
GTHX
|
-135.55 | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
0.28 | - | - | $ 621 M | Britain |
 |
MediWound Ltd.
MDWD
|
-126.46 | $ 14.18 | 6.38 % | $ 386 M |  Israel |
 |
Kinnate Biopharma
KNTE
|
-70.7 | - | - | $ 123 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-64.24 | - | - | $ 7.29 B | USA |
 |
Nektar Therapeutics
NKTR
|
-182.65 | $ 37.25 | 3.04 % | $ 628 M | USA |
 |
Immunome
IMNM
|
-33.48 | $ 18.71 | 4.5 % | $ 1.63 B | USA |
 |
NexImmune
NEXI
|
-921.57 | - | 70.13 % | $ 4.12 M | USA |
 |
Kala Pharmaceuticals
KALA
|
-385.65 | $ 0.16 | 2.1 % | $ 1.3 M | USA |
 |
Theravance Biopharma
TBPH
|
35.69 | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M |  Canada |
 |
Karuna Therapeutics
KRTX
|
-34.58 | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
-72.64 | - | - | $ 756 M | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-130.27 | - | - | $ 229 M | USA |
|
89bio
ETNB
|
-91.59 | - | - | $ 1.55 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-42.65 | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
-267.1 | - | 0.42 % | $ 213 M | USA |
 |
Harpoon Therapeutics
HARP
|
-1254.51 | - | - | $ 763 M | USA |
 |
HOOKIPA Pharma
HOOK
|
-84.94 | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
1.94 | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
6.42 | - | - | $ 109 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
-93.21 | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
Seagen
SGEN
|
-21.77 | - | - | $ 42.2 B | USA |
 |
Baudax Bio
BXRX
|
242.53 | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
-14.16 | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-231.16 | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
-90.75 | - | 7.23 % | $ 2.72 M | USA |
 |
Oncternal Therapeutics
ONCT
|
-131.37 | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
607.06 | - | - | $ 591 K |  Irlanda |
 |
Spectrum Pharmaceuticals
SPPI
|
-270.37 | - | - | $ 189 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-9.81 | - | - | $ 2.17 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
-71.33 | - | - | $ 401 M | USA |